■ Spotlight on New Three Board Sichuan Enterprises
July 22, 2019 is destined to be a memorable day for China's multi-level capital market. On this day, the Science and Technology Innovation Board (STIB) will officially sound the gong to open the market, and the first 25 companies will be the first to shortcut the market. Although there is no Sichuan enterprises among them, many Sichuan enterprises, especially those that are or have been listed on the New Third Board, are still eager to try. They are not only ready to transfer to the Science and Technology Innovation Board, but will also transfer to other boards for listing according to their actual situation. Financial Investment News reporter combed through and found that the new three board Sichuan enterprises, Yuandong biological, Baiyu pharmaceutical has been submitted to the SSE Kechuan board listing application; originally prepared to be listed on the GEM Junyi digital adjusted the listing plan, may be changed to the Kechuan board listing; Hai Nuoer to the Securities and Futures Commission to submit an application for listing on the GEM board and accepted; in addition, Zigong, and a number of other companies are waiting to be launched.
■ Our reporter Yang Chengwan
Science and Technology Innovation Board Yuan Dong Biological was asked by the SSE
Yuan Dong Biological sprinting to the Science and Technology Innovation Board has new progress. The company has been asked by the SSE on July 17th. The company is sponsored by CITIC Securities, Beijing Guofeng Law Firm provides legal services for it, and Zhonghui Accounting Firm (special general partnership) provides accounting and auditing services. The company has terminated its listing since April 12, 2017 on the New Third Board.
Fundamentals show that the company is based on high-end chemical drugs, focusing on innovative drugs and seeking development with biological drugs. The company has set up two research and development organizations and one biological drug research and development company, covering the research and development of chemical APIs, chemical pharmaceutical preparations and biological drugs. The R&D center of chemical pharmaceutical preparation is set up in Yuandong Bio, the R&D department of chemical API is set up in the subsidiary company Qingmu Pharmaceutical, and the subsidiary company Youluo Bio is responsible for the implementation of the R&D of biopharmaceuticals. The company's R&D center is recognized as the Sichuan Provincial Enterprise Technology Center, and the Yuan Dong Biological Branch of Chengdu Hi-Tech Zone Postdoctoral Research Station is also set up.In 2018, the company's R&D expenses reached 124 million yuan, accounting for 16.18% of the operating income.
The company adheres to independent research and development of core technologies, and at the same time, it adopts cooperation with domestic and foreign famous research institutes and qualified CRO companies in some of the R&D processes. The company has established a complete set of mechanisms for screening, evaluation and control of cooperative organizations to ensure efficient project cooperation results.
The company's R&D personnel total 187, accounting for 28.9% of the company's total headcount; among them, there are 2 experts under the Thousand Talents Program of Sichuan Province, 2 experts under the Talents Program of Chengdu Municipality, and 70 master's/doctoral degree holders accounting for 37.4% of the R&D personnel, with 86% of the personnel with bachelor's degree or above in pharmaceuticals. The company's R&D team has been recognized as "Innovative Drug R&D Team in Major Diseases" in Sichuan Province. The company has 6 core technicians who have led many R&D projects.
BAYU Pharmaceuticals has filed an application for IPO on the Shanghai Stock Exchange. Founded in 2005, the company had been listed on the New Third Board in 2016 and terminated its listing on the New Third Board from the end of June 2017 onwards. The company is a modernized traditional Chinese medicine enterprise focusing on cardiovascular and cerebrovascular diseases, resistance to infectious diseases, neurological diseases and other fields. With a cumulative R&D investment of nearly 200 million yuan in the past three years, it has 24 drug production approvals, 22 drug clinical approvals, and more than 50 other products under research and development. Among them, Ginkgolide injection is the first new Chinese medicine injection approved since the implementation of the new drug registration management method in 2007, with more than 99% active ingredients.
GEM Hainuoer's listing application was accepted
Hainuoer was listed on the New Third Board on November 2, 2015, and from 2017, the company has stayed in the innovation layer for three consecutive years. The company's listing direction is GEM. On June 20 this year, the company submitted an application to the Securities and Futures Commission (SFC) for an initial public offering and listing on GEM and has been accepted by the SFC. At the same time, the company submitted to the national stock transfer company to suspend the transfer of the company's shares.
It is worth noting that on July 11, Junyi digital announcement that the company carefully studied and prudent decision to adjust the listing plan to the Securities and Exchange Commission to apply for the withdrawal of the listing materials. It is reported that the company had on January 7 this year, to the Sichuan Securities Regulatory Bureau submitted to the Shenzhen Stock Exchange GEM initial public offering and listing counseling filing materials, the proposed issuance of 25.8 million shares, accounting for the issuance of the company's total share capital of 25.10%. Sichuan Supervision Bureau has made a public announcement on the official website on January 8 this year. The company is currently under the counseling of Hualin Securities.
Junyi Digital was listed on the New Third Board on March 28, 2016, and is still listed on the New Third Board, and during the listing period, it has completed a fixed-price increase to raise funds of 45 million yuan, as well as two dividends. However, in order to cooperate with the transfer plate listing, from May 29 this year, the company's shares suspended in the new three board market transfer. "Continue to seek the road to listing is certain, do not rule out the transfer board to the science and innovation board, just has not yet been confirmed by accurate news." Some industry insiders said.
Junyi Digital's main business is to use the Internet of Things, cloud computing, big data, BIM and other new-generation smart city application technology, to provide customers with a set of customized development of application software and intelligent, information technology system integration services as one of the smart city industry integrated solutions. 2018 to achieve operating income of 318 million yuan, realizing a net profit of 55.2211 million yuan.
New Three Board Many companies receive listing counseling
While a few companies have caught the "first train" on the KTB, most are doing so by making their main business bigger and stronger and standardizing their operations. The first is to continue to stay in the innovation layer of the Zigong this year, which is listed in Sichuan Province as "counseling for the record enterprises". The company has two subsidiaries, three production bases, 98 production approvals and four new drug certificates. The company adopts two sales modes: agency and investment, supplemented by specialized academic promotion. 2018 achieved operating income of 277 million yuan, and realized a net profit of 42.3624 million yuan.
Sichuan Weihong, also listed as a "counseling record enterprise" in Sichuan Province, relies on the rich local land, forest and water resources in Qingchuan County, and adopts the cooperative planting mode of "company + base + farmers" to engage in the research and development, planting, production, processing and sales of edible fungi, production, processing and sales.In 2018, it realized an operating income of 122 million yuan and a net profit of 24.568 million yuan.
Laokeng Medical is also a "counseling record enterprise" in Sichuan Province, mainly engaged in the research and development, production and sales of hospital infection control equipment, providing hospitals with the overall solution of disinfection supply center (CSSD), disinfection and sterilization outsourcing services, and the overall solution of pharmacy automation. 246 million yuan, and realized a net profit of 6,067,400 yuan.
In addition, as a "counseling record enterprise" in Sichuan Province, Jing Yunxiang, with industry access qualifications and a number of patented technologies, such as the first level of general contracting for the construction of communications engineering, China Tower, China Mobile, China Telecom, China Unicom, including the system integration of communications engineering, the production and supply of communications equipment, communications systems, integrated maintenance, communications facilities leasing, including the system integration of communications engineering, communications equipment production and supply, communications systems, integrated maintenance, communications facilities leasing. comprehensive maintenance, communication facilities leasing, and a series of services.In 2018, it realized an operating income of 630 million yuan and a net profit of 8,897,900 yuan.
The company is engaged in the research and development, production and sales of digital television and audio broadcasting front-end and transmission systems, emergency broadcasting systems, and is also a "counseling record enterprises" in Sichuan Province. The company from market research, R & D project, R & D design to product promotion to implement the whole quality management. 2018 to achieve operating income of 229 million yuan, net profit of 50.5325 million yuan.